Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Fevertree Drinks Plc LSE:FEVR London Ordinary Share GB00BRJ9BJ26 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -18.00 -1.56% 1,134.00 344,740 16:35:12
Bid Price Offer Price High Price Low Price Open Price
1,122.00 1,128.00 1,151.00 1,118.00 1,134.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Beverages 311.10 55.60 38.29 29.6 1,322
Last Trade Time Trade Type Trade Size Trade Price Currency
18:28:20 O 10,893 1,134.982 GBX

Fevertree Drinks (FEVR) Latest News

More Fevertree Drinks News
Fevertree Drinks Investors    Fevertree Drinks Takeover Rumours

Fevertree Drinks (FEVR) Discussions and Chat

Fevertree Drinks Forums and Chat

Date Time Title Posts
02/2/202319:25FEVER TREE with chart8,413
24/11/202212:15Fevertree156
28/1/202209:55Fevertree Drinks PLC (Fever-Tree)1,964
26/11/202111:18Fevertree - private investor971
26/3/201910:54Fevertree Drinks FY Results 26.03.19 Preview5

Add a New Thread

Fevertree Drinks (FEVR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-02-03 18:28:201,134.9810,893123,633.59O
2023-02-03 17:56:401,134.0018204.12O
2023-02-03 17:56:081,134.002,73130,969.54O
2023-02-03 17:56:081,134.0028317.52O
2023-02-03 17:32:301,138.961,49417,016.12O
View all Fevertree Drinks trades in real-time

Fevertree Drinks (FEVR) Top Chat Posts

Top Posts
Posted at 04/2/2023 08:20 by Fevertree Drinks Daily Update
Fevertree Drinks Plc is listed in the Beverages sector of the London Stock Exchange with ticker FEVR. The last closing price for Fevertree Drinks was 1,152p.
Fevertree Drinks Plc has a 4 week average price of 944.50p and a 12 week average price of 944.50p.
The 1 year high share price is 2,259p while the 1 year low share price is currently 804.50p.
There are currently 116,562,434 shares in issue and the average daily traded volume is 497,064 shares. The market capitalisation of Fevertree Drinks Plc is £1,321,818,001.56.
Posted at 26/1/2023 21:12 by topvest
I am a big fan of Fevertree and am particularly partial to the Elderflower Light Tonic Water.
I would probably invest in the company at a sensible price given its potential for growth outside the UK.
A P/E of c50 and a dividend yield of c1% is not sensible though. Nick Train - what were you thinking?
Its at least 100% higher than it should be.
Lets face it its gone ex-growth in the UK already. Its also been on the wrong end of inflation not being able to fully pass on its cost increases because it has an outsourced production and too high a glass bottle mix.
Personally, I buy the cans and prefer those. Why don't they switch more from bottles to cans?
13% constatnt currency growth in the US was nothing to shout out about either. What about volumes?

Posted at 26/1/2023 09:19 by castleford tiger
in Nov I warned UK sales were poor.

EDWARDT tells us glass is down a chunk.!!

However, the impact of elevated European energy costs into glass bottle pricing will be material in 2023. Whilst energy pricing has recently reduced, it remains volatile and at least three times higher than 2021 levels, impacting both the cost of raw materials and the direct energy cost in glass manufacture.

-- As a glass-led business, with c.80% of our sales mix in glass bottles, we are particularly exposed to this significant headwind. We now estimate that the direct energy component of glass manufacture alone represents a c.GBP20m additional cost to the business in 2023 compared to our prevailing glass pricing in Q1 2022

The above backs me up that glass is still going up in price.

I expect more bad news to come especially on MARGINS

Tiger

Posted at 24/11/2022 12:15 by albert arthur
Blackrock have short covered 1.8% of short in #FEVR since November 15th, the price has risen 11.51% since. One to watch, expect continued covering. They still hold a 4.47% short there.Graphs here: https://twitter.com/albert__arthur/status/1595747220724355073?s=46&t=190Bl7cmfKf_th4tMgZu7g
Posted at 31/10/2022 18:07 by valuehurts
When I pay the extortionate price of a G&T when I'm out I expect not just Fevertree but the finest Gin, perfectly cold glass, freshly chipped Ice from the barren wilderness of Alaska. A slice of the finest lemon brought to the UK individually by the owner of said establishment, picked by his own hand alone and the pretty waitress to perform a little dance with sparklers.
Posted at 14/10/2022 14:17 by rndm355
FEVR discussed for 25 mins here:

hTTps://www.youtube.com/watch?v=TajjL8DXJAU

Posted at 10/10/2022 09:41 by philanderer
HSBC raises Fevertree Drinks to 'hold' (reduce) - price target 800 (780) pence
Posted at 14/9/2022 22:21 by valuehurts
When will they just raise prices. Every time I see the product they seem to be competing with Schweppes on price. Bad for the brand. It's like LVMH trying to compete with Micheal Kors by lowering prices and trying to sell more handbags. Suicidal.. keep it a expensive. It's worth it...
Posted at 15/7/2022 08:13 by kinwah
It's interesting on glass prices. FEVR has its own moulds for its bottles so it has almost zero short-term bargaining power on bottle prices. I buy ale at Tesco taking advantage of 4 for £6. Some ales with their own moulded bottles have left the promotion and are now priced separately at £1.59. Any new ales joining the promotion have generic bottles. It suggests maybe an increase of about 5p in the cost of a 500ml bottle. Ouch!
Posted at 28/1/2022 13:47 by toffeeman
Mixed feelings for posh tonic maker Fever-Tree
Emma Powell
Friday January 28 2022, 12.01am, The Times
You’d think that investors would have learnt to be pessimistic when it comes to Fever-Tree’s earnings. Chasing market share has come at a price of heavy costs and margins that have shrunk over the past five years. And the prospect of any relief to all that has been hit by rapidly rising inflation.
Higher transatlantic freight costs and raw materials prices mean that stronger sales won’t feed through to better earnings. The drinks group has guided towards earnings before interest, tax and other charges of between £69 million and £72 million for this year, below an analyst consensus forecast of £75 million. A margin that had been expected to return to growth is now set to be flat on last year at about 20 per cent.
The maker of posh tonics has capitalised on the revival of gin in Britain and fancier tastes among drinkers willing to spend more on mixers. Rapid revenue growth had made the Aim-listed group a stock market darling, spurring a rise in the shares of more than 2,000 per cent between 2014 and a 2018 peak. But concerns over a slowdown in sales growth within a maturing UK market and the hefty costs associated with international expansion have hamstrung the shares since then.
Pandemic impact aside, some of the challenges to margins have been one-offs, such as cash spent on cutting prices in the United States in 2020. But investment in adding customers — including hiring staff, marketing and taking on new premises — is a recurring drain on funds. Analysts at Liberum, who downgraded the stock from a “buy” to a “hold” on the back of yesterday’s trading update, cut their adjusted earnings forecasts for this year and next by 10 per cent, to £71.9 million and £89.7 million, respectively. The company reckons the margin will return to growth next year, which Liberum interprets as an adjusted pre-tax margin of 21.6 per cent. Bringing distribution closer to international markets should provide some relief against freight costs. A bottling facility on the east coast of America is due to step up production in the coming months; another is due to open in Australia next year.
The premium tonic specialist argues that gaining market share is the main prize and it is willing to sacrifice margins to attain that, for now. Admittedly, revenue growth has been impressive, up almost a quarter last year and ahead of the level suggested in September. Revenue guidance for this year has been upgraded, too, encouraged by a recovery in higher-margin on-trade sales as pubs and bars reopen and expectation that at-home demand will stick above the pre-pandemic level.
Heady sales expectations are built into the group’s enterprise value, which sits at almost eight times forecast sales for next year. That’s even after some froth coming out of the shares, which are down just over 40 per cent from their peak. But given the continued margin pressure, a share price that represents 51 times forward earnings, above an historic multiple of 45, is problematic.
Efforts to maintain strong revenue growth could continue to have two negative side-effects. First, it means the drinks specialist will need to keep investing in staff, marketing and general product development as it seeks to broaden its range of mixers beyond its staple tonic and to expand further in America. Second, it limits the ability to push through price increases that would be substantial enough to ease pressure on margins, particularly given uncertainty over how long materials inflation and higher freight costs persist. You can understand that reluctance, to some extent, but it also means the shares are at risk of further punishment.
Advice Avoid
Why The current valuation leaves little room for error, which could materialise if inflation persists for longer than anticipated

Posted at 26/1/2022 16:01 by martywidget
LON:FEVR - Fevertree Drinks Stock Price Target and Predictions:

htTPS://www.pricetargets.com/LON/FEVR/


Fevertree Drinks (LON:FEVR)'s stock had its "neutral" rating restated by Citigroup in a report issued on Wednesday, Price Targets.com reports. They presently have a GBX 2,300 ($31.03) price objective on the stock. Citigroup's target price would suggest a potential downside of 6.15% from the stock's previous close.

Several other research firms have also issued reports on FEVR. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of Fevertree Drinks in a research note on Wednesday, January 19th. Barclays increased their target price on Fevertree Drinks from GBX 2,400 ($32.38) to GBX 3,350 ($45.20) and gave the stock an "overweight" rating in a research note on Tuesday, December 14th. Deutsche Bank Aktiengesellschaft increased their target price on Fevertree Drinks from GBX 3,300 ($44.52) to GBX 3,560 ($48.03) and gave the stock a "buy" rating in a research note on Tuesday, January 18th. Finally, Berenberg Bank reiterated a "buy" rating and set a GBX 2,700 ($36.43) target price on shares of Fevertree Drinks in a research note on Wednesday, January 5th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of GBX 2,601.11 ($35.09).

www.marketbeat.com/instant-alerts/lon-fevr-a-buy-or-sell-right-now-2022-01-2-3/

Fevertree Drinks share price data is direct from the London Stock Exchange
Your Recent History
LSE
FEVR
Fevertree ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230204 16:43:23